NEW YORK, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)DANIEL W OFFIT FUND TO FIGHT GLIOBLASTOMA INC, founded in 2024, is a small nonprofit in the Medical Research sector that reported $629K in total revenue in fiscal year 2024. The organization ran a surplus of $532K, a strong 85% operating margin.
THE DANIEL W. OFFIT FUND TO FIGHT GLIOBLASTOMA IS DEDICATED TO ADVANCING GLIOBLASTOMA RESEARCH AND THERAPIES.
THE DANIEL W. OFFIT FUND TO FIGHT GLIOBLASTOMA, INC. (THE ORGANIZATION) PLANS TO FUNDRAISE TO FUND RESEARCH AND THERAPIES FOR CANCER, INCLUDING IN PARTICULAR GLIOBLASTOMA. THE GLIOBLASTOMA MULTIFORME...
THE DANIEL W. OFFIT FUND TO FIGHT GLIOBLASTOMA, INC. (THE ORGANIZATION) PLANS TO FUNDRAISE TO FUND RESEARCH AND THERAPIES FOR CANCER, INCLUDING IN PARTICULAR GLIOBLASTOMA. THE GLIOBLASTOMA MULTIFORME (GBM) IS THE MOST COMMON AND DEADLIEST FORM OF ADULT BRAIN CANCER. TO DATE THERE HAS BEEN LITTLE PROGRESS MADE IN IDENTIFYING A CURE FOR THIS DISEASE, WITH THE AVERAGE LIFE EXPECTANCY AFTER DIAGNOSIS SADLY BEING AROUND 14 MONTHS. (CONTINUED SCHED O)(CONTINUED FROM PAGE 2, PART III, 4A) THE ORGANIZATION INTENDS TO FUNDRAISE FROM THE PUBLIC, INCLUDING THROUGH FUNDRAISING EVENTS, AND ALL OF THE FUNDS RAISED BY THE ORGANIZATION WILL BE USED TO FUND AND ADVANCE FURTHER RESEARCH AND THERAPIES FOR CANCER, INCLUDING IN PARTICULAR GBM.THE ORGANIZATION INTENDS TO HAVE A SCIENTIFIC ADVISORY BOARD (SAB), WHICH WILL BE COMPOSED OF EXPERT MEDICAL AND RESEARCH PROFESSIONALS, TO ADVISE THE ORGANIZATION ON THE PROJECTS THAT HAVE THE MOST VIABLE PATH TO A CURE FOR GBM. THE ORGANIZATION WILL USE THE FEEDBACK OF ITS SAB TO DETERMINE THE MOST IMPORTANT RESEARCH PRIORITIES AND TO SOLICIT AND FUND RESEARCH PROPOSALS AIMED AT ADDRESSING THESE PRIORITIES. THE ORGANIZATION WILL ENSURE THAT ANY GRANTS IT MAKES ARE SELECTED AND DISTRIBUTED THROUGH AN OPEN AND DISINTERESTED PROCESS AND THROUGH EXISTING ACADEMIC AND PROFESSIONAL INFRASTRUCTURES.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $629,357 | N/A | N/A |
| Expenses | $97,425 | N/A | N/A |
| Net Income | $531,932 | N/A | N/A |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| MORRIS OFFIT | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| NED OFFIT | PRESIDENT | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| VINCENT RELLA | SECRETARY/TREASURER | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $629,357 | $97,425 | $538,884 | $531,932 |
Compare DANIEL W OFFIT FUND TO FIGHT GLIOBLASTOMA INC with other nonprofits in New York and across the country.